Toragen
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Biolabs San Diego at 10210 Campus Point ...Website
www.toragen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Toragen
Founded in 2016 and headquartered in San Diego, California, Torgen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Toragen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Toragen recently announced quarterly report
Check if Toragen has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Toragen
Toragen, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Toragen launches new products
Funding: Get notified immidiatlly once Toragen has new funding data
Website visits: Recent activity has been detected on your website
Check out if Toragen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Toragen had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Toragen
Find 3 more new buyers
Compare Similar Companies to Toragen
Compare insights from companies similar to Toragen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Toragen
<$5M
1-10
Private
$5M
2016
N/A
Company Profile Activity
Activity Insights
Toragen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Toragen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Toragen.
Toragen financials insights
Gather financial insights about Toragen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$5M
Toragen Tech Stack
A closer look at the technologies used by Toragen
Most Recent Scoops
Promotion
Executive Move
New Hire
Executive Move
Funding
Funding
Toragen News & Media
Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 2 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being coToragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being coToragen, Inc. Announced Full Enrollment of Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer
SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced that it has fully enrolled patients in Cohort 1 of its Phase 1 clinical study to evaluate TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associatedToragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer
SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, today announced that it has initiated a Phase 1 clinical trial to evaluate its first drug candidate (TGN-S11). It is believed that HPV survives within the cells and can eventually cause cancer by blocking immune responses and going undetected by the immune system. Toragen’s drug candidate, TGN-S11, inhibits the E5 o
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Toragen
Sign Up For FreeTo access detailed company insights
Founded in 2016 and headquartered in San Diego, California, Torgen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers.... Read More
